U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07641257) titled 'Effects of Icosapent Ethyl on Coronary Plaque, Inflammation, and Ventricular Remodeling' on May 25.
Brief Summary: Even with standard treatments like statins, patients with coronary artery disease often face a residual risk of further heart events. This risk is largely driven by ongoing inflammation and unstable fatty plaques in the heart's blood vessels. Icosapent ethyl (IPE) is a highly purified prescription medication known to improve cardiovascular outcomes, but its detailed effects on the heart's structure and inflammation in everyday clinical practice need further exploration.
This study is a prospective, observational, real-...